48 results on '"Janku, Filip"'
Search Results
2. Abstract LB057: Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST)
3. Abstract 575: Enhancing cell-free DNA mutation detection with novel liquid-phase extraction
4. Abstract 2710: The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers
5. Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF
6. Abstract CT108: A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors
7. Abstract LB031: Plasma based metabolic profiling in metastatic gastrointestinal stromal tumors (GIST)
8. Abstract 564:BRAFV600mutation in circulating tumor DNA can predict outcomes in early-stage melanoma
9. Abstract PO-208: Patient-reported out-of-pocket costs and financial toxicity during early- phase oncology clinical trials
10. 383 First-in-man clinical trial of intratumoral injection of clostridium Novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors
11. 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies
12. Abstract B17: Activating mutations of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene confer sensitivity to PD-L1 checkpoint inhibition in metastatic adenocarcinoma patients
13. Abstract B07: TAK228 enhances antitumor activity of eribulin in triple-negative breast cancer
14. Abstract P1-19-18: Everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic cancer: Evaluating synergy and overcoming resistance
15. Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)
16. Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs)
17. Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors
18. Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations
19. Abstract 573: BRAF, KRAS, and NRAS mutations in archival tumor samples and samples of cell-free DNA from serum and bone marrow aspirates from patients with multiple myeloma
20. Abstract 642: Detection of circulating antibodies against KRAS in patients with advanced cancers
21. Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma
22. Abstract 5381: A highly sensitive method for noninvasive cancer profiling through targeted methylation sequencing of circulating cell-free DNA
23. Abstract LB-016: Angiogenin contributes to bladder cancer tumorigenesis by facilitating p53 mediated activation of MMP2
24. Abstract 3291: Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials
25. Abstract 4573: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
26. Abstract LB-039: Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor
27. Abstract 5687: Detection and monitoring of IDH mutations in unamplified plasma cell-free DNA in patients with advanced cancers treated with IDH inhibitors
28. Abstract 493: Quantity of KRAS mutations in cell-free DNA is associated with survival of patients with advanced cancers
29. Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium
30. Abstract CT052: A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a BRAF aberration
31. Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response
32. Abstract CT098: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors
33. Abstract CT240: Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I dose-expansion study in patients with squamous cell carcinoma of the head and neck
34. Abstract 2689: Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study
35. Abstract 2413: Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform
36. Abstract 2407: MultiplexKRASG12/G13 mutation testing of 16ng of unamplified cell-free DNA from plasma of patients with advanced cancers using Droplet Digital PCR
37. Abstract 604: Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary: Implications for personalized medicine
38. Abstract 4263: Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials
39. Abstract 246: Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers
40. Abstract LB-176: Identification of mutations in histone modification genes in Hodgkin lymphoma
41. Abstract 2414: Novel, ultra deep next-generation sequencing of plasma cell-free DNA from patients with advanced cancers
42. Abstract 2827: Association between new onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor (TKI) therapy in phase I clinical trials
43. Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS).
44. Abstract C203:BRAFandKRASmutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers.
45. Abstract 1178: Phase I clinical trial of Lenalidomide in combination with Sorafenib in patients with advanced cancer.
46. Abstract LB-446: Target-based therapeutic matching in patients withPIK3CAmutations and PTEN aberrations
47. Abstract 1279: Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors
48. Highlights from the 7th Central European Lung Cancer Conference
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.